JNJ - Johnson & Johnson
| Previous Close | 139.50 |
| Open | 138.34 |
| Bid | 138.70 x 900 |
| Ask | 139.30 x 800 |
| Day's Range | 137.91 - 140.00 |
| 52 Week Range | 118.62 - 148.32 |
| Volume | 5,924,814 |
| Avg. Volume | 6,190,678 |
| Market Cap | 373.038B |
| Beta (3Y Monthly) | 0.53 |
| PE Ratio (TTM) | 276.44 |
| EPS (TTM) | 0.50 |
| Earnings Date | Jan 21, 2019 - Jan 25, 2019 |
| Forward Dividend & Yield | 3.60 (2.58%) |
| Ex-Dividend Date | 2018-08-27 |
| 1y Target Est | 145.63 |
Market Realist•2 days agoAn Overview of JNJ’s Women’s Health & Wound Care Businesses
Johnson & Johnson’s (JNJ) women’s health business generated revenue of $269.0 million in the third quarter compared to $270.0 million in the third quarter of 2017. In the US and international markets in the quarter, the business generated revenues of $3.0 million and $266.0 million, respectively.
Market Realist•2 days agoA Performance Overview of JNJ’s Beauty and OTC Businesses
Johnson & Johnson’s (JNJ) beauty business generated revenue of $1.1 billion in the third quarter compared to $1.0 billion in the third quarter of 2017, reflecting a ~4.4% YoY rise.
- Motley Fool•2 days ago
What's Behind Johnson & Johnson's Q3 Earnings Success
Here's why this healthcare giant is out-performing analyst expectations.
- Market Realist•2 days ago
What’s Pfizer’s Current Valuation?
In this part, we’ll compare Pfizer’s (PFE) valuation with its peers including Merck (MRK), Johnson & Johnson (JNJ), Eli Lilly (LLY), and Bristol-Myers Squibb (BMY).
- Market Realist•2 days ago
Pfizer’s Dividends and Earnings Quality
In this part, we’ll discuss Pfizer’s (PFE) earnings quality and dividend performance. The above chart compares the changes in Pfizer’s Earnings Quality score since the first quarter of 2017. Pfizer has announced the following dividends during 2018.
- Kiplinger•2 days ago
10 S&P 500 Stocks to Buy for the Long Term
The last few days have been tough ones for too many investors in S&P 500 stocks. Though far from devastating, the existing backdrop of anxiety exacerbated the fear incited by the modest selloff. And traders still aren't sure what the foreseeable future holds. In simplest terms, it's just plain stressful. It's times like these when the "old school" approach of buy and hold -- meaning buy it and forget about it -- starts to sound compelling again. In other words, forget the day-to-day battles. Sit back and trust that time will do the heavy lifting for you. To that end, here's a rundown of 10 large-cap names that are well-suited for that precise approach. They're all S&P 500 stocks, and more than that, they're all names that don't require constant babysitting. You can count on them more or less being the same company a year from now, and even five years from now. In no particular order... SEE ALSO FROM KIPLINGER: 10 S&P 500 Stocks to Buy for Long-Term Outperformance
- Market Realist•2 days ago
Pfizer Reported Revenue Growth in Global Markets
Pfizer (PFE) reported revenue growth in international markets during the second quarter. Lower sales from US markets offset the growth during the quarter.
- Motley Fool•3 days ago
Can UnitedHealth Group and Johnson & Johnson Continue Their Winning Ways?
How these healthcare giants beat industry watchers' estimates last quarter and their plans for the future.
- Investing.com•3 days ago
Intuitive Surgical Earnings miss, Revenue beats In Q3
Investing.com - Intuitive Surgical (NASDAQ:ISRG) reported third quarter earnings that missed analyst's expectations on Thursday and revenue that topped forecasts.
- Market Realist•3 days ago
Pfizer’s Growth Rate and Estimates
Pfizer (PFE) reported an EPS of $0.74 on revenues of ~$13.5 billion during the second quarter, which beat analysts’ estimate of ~$13.3 billion.
- Zacks•3 days ago
Johnson & Johnson, Community Healthcare Trust: Income Stocks to Watch
Ryan McQueeney puts two income stocks --- Johnson & Johnson (JNJ) and Community Healthcare Trust (CHCT)---in the spotlight this week. JNJ delivered impressive earnings a few days back, while CHCT is an interesting REIT to watch in current conditions.
- Market Realist•3 days ago
Novartis Missed Revenue Estimates in Q3 2018
Novartis (NVS) released its third-quarter earnings results on October 18. The company surpassed Wall Street analysts’ consensus estimate for EPS but missed their estimate for revenue in the quarter. Novartis reported EPS of $1.32 on revenue of ~$12.78 billion compared to analysts’ estimate of EPS of $1.31 on revenue of ~$13.02 billion.
- Market Realist•3 days ago
Pfizer’s Market Cap and Shareholding Pattern
As we discussed earlier, Pfizer’s (PFE) product portfolio is classified into two segments—the Innovative Health segment and the Essential Health segment. In this part, we’ll discuss Pfizer’s market capitalization and shareholding pattern.
- Market Realist•3 days ago
Analyzing Pfizer’s Stock Performance in October
Pfizer (PFE) is one of the leading healthcare companies. Pfizer stock increased 1.5% and closed at $44.57 on October 17—compared to the previous close.
- PR Newswire•3 days ago
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2018
NEW BRUNSWICK, N.J., Oct. 18, 2018 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2018 of $0.90 per share on the company's common stock. The dividend is payable on December 11, 2018 to shareholders of record at the close of business on November 27, 2018. At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress.
- Motley Fool•4 days ago
2 Big Pharmas Pleased With J&J's Third-Quarter Earnings Report
Johnson & Johnson's latest earnings report suggests pricing concerns in the U.S. are overblown for pharmaceutical stocks with strong oncology exposure. Here's what you need to know.
- American City Business Journals•4 days ago
They tackled chronic cough. Now with $54.5 million, this duo is targeting Alzheimer's and more
After taking a Peninsula startup through a billion-dollar acquisition, Kathy Glaub and Anthony Ford are at it again. The duo are leading CuraSen Theraepeutics Inc., which said Wednesday that it had raised $54.5 million to target Alzheimer's disease, Parkinson's disease and other, less-common neurodegenerative diseases. The Series A round was led by New Leaf Venture Partners and included Longitude Capital, funds managed by Tekla Capital Management LLC, Alta Partners, Pappas Capital and Johnson & Johnson's corporate venture arm.
- Thomson Reuters StreetEvents•4 days ago
Edited Transcript of JNJ earnings conference call or presentation 16-Oct-18 12:30pm GMT
Q3 2018 Johnson & Johnson Earnings Call
- Investing.com•4 days ago
Abbott Labs Earnings, Revenue beat in Q3
Investing.com - Abbott Labs (NYSE:ABT) reported third quarter earnings that beat analyst's expectations on Wednesday and revenue that topped forecasts.
- Zacks•4 days ago
Stock Market News For Oct 17, 2018
Wall Street rebounded on Tuesday as stocks surged across the board due to strong third-quarter 2018 earnings results and impressive economic data.
- ACCESSWIRE•4 days ago
Today's Research Reports on Trending Tickers: vTv Therapeutics and Johnson & Johnson
NEW YORK, NY / ACCESSWIRE / October 17, 2018 / U.S. equities closed higher on Tuesday, driven by upbeat corporate earnings and strong economic data. According to the Federal Reserve, U.S. industrial production ...
Associated Press•4 days agoAsian shares climb on strong US corporate earnings, data
SINGAPORE (AP) — Asian markets rose on Wednesday as robust U.S. corporate earnings and encouraging data assuaged worries about softening global growth.
- TheStreet.com•5 days ago
The Rally We've Been Waiting For: Cramer's 'Mad Money' Recap (Tuesday 10/16/18)
"When the Fed bears are away, the stock bulls will play," Jim Cramer told his Mad Money viewers Tuesday, after the markets mounted an impressive relief rally. Cramer reminded viewers that a panic is a terrible thing to waste, which is why the smart money was buying into the recent declines and not selling out of fear.
- The Wall Street Journal•5 days ago
[$$] Prescription Drugs Power Johnson & Johnson Results
Johnson & Johnson reported higher revenue and profit for the third quarter, as improved pharmaceutical sales helped offset weakness in its medical-device business. Global sales of J&J’s cancer drugs, which include Zytiga for prostate cancer and blood-cancer treatments Darzalex and Imbruvica, jumped 36% for the quarter. “Our positive view on pharma is offset by ongoing challenges to the company’s medical device and consumer franchises,” JPMorgan analyst Chris Schott wrote in a research note.
Yahoo Finance Video•4 days agoSTOCKS on the move: Netflix, Facebook, McDonald's, J&J, Home Depot, IBM
Live from the floor of the New York Stock Exchange, Yahoo Finance's Jared Blikre joins Alexis Christoforous to discuss the latest market moves.
